biliary tract cancer

biliary tract cancer

a rare adenocarcinoma in a bile duct often causing jaundice, pruritus, and weight loss. The lesion may be papillary or flat and ulcerated. The tumor is often unresectable at diagnosis.
References in periodicals archive ?
3,4] These emerging applications include the use of BAs as biomarkers for the detection of biliary tract cancer, metabolic profiling of patients with gastrointestinal disorders to optimize treatment outcomes, and identifying additional biomarkers for liver diseases such as obstetric cholestatis, a liver disorder associated with adverse perinatal outcomes.
Vagaries of clinical presentation of pancreatic and biliary tract cancer.
Specialists in oncology, radiology, surgery, and other areas consider such topics as pathologic staging, diagnostic magnetic resonance imaging, surgical management of intra-hepatic biliary tract cancer, radiation therapy, and symptom management and palliation.
The agent will now be available for the treatment of biliary tract cancer.
Cancer: Chronic high consumption of refined sugar is associated with biliary tract cancer (especially if you have gallstones), colon cancer, breast cancer, endometrial cancer, and stomach cancer.
Recent studies from Japan have suggested that anatomical anomalies of the pancreaticobiliary tree are associated with biliary tract cancer.
Array advanced MEK162 in an expansion of a Phase 1 trial of MEK162 in biliary tract cancer patients at ten clinical sites in North America.
Biliary Tract Carcinoma Study Highlights Investigators used Caris Molecular Intelligence to evaluate 815 cases of biliary tract cancer (126 EHCC, 434 IHCC, 244 GBCA, 11 Not Otherwise Specified) to delineate different molecular alterations within those tumors as a means to identify potential therapeutic options.
Topics include: cholecystic venous system and liver metastasis from gallbladder carcinoma, tumor angiogenesis, external palliative radiotherapy, gallbladder cancer risk in patients with a long common channel, and experimental strategies to treating biliary tract cancer, among others.
Approximately 60-80% of patients with hepatocellular and 75-100% of those with biliary tract cancer have increased TATI.
Array will continue to advance MEK162 into an expansion phase of a Phase 1 trial at the maximum tolerated dose in biliary tract cancer patients at ten clinical sites in North America.
We have also found increased concentrations of trypsin-1-AAT in patients with biliary tract cancer (32).